LCTX News and Press, BioTime Inc.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...

Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...

2024-05-10 00:33:02 ET Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Conference Call May 09, 2024 04:30 PM ET Company Participants Ioana Hone - Head, Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Con...

2024-05-09 16:22:10 ET More on Lineage Cell Therapeutics Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell Therapeutics Financial ...

Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit OpRegen Preclinical Results Pre...

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10) BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5) Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) laye...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the...

2024-04-29 16:39:40 ET More on Lineage Cell Therapeutics Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell Therapeutics Financial ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley’s family for their loss. Mr. Kingsley served as Chairman of ...